Key takeaways
- Medifast reported a narrower Q3 2026 loss of $0.19 per share and revenue of $72.00 million, both exceeding analyst estimates.
- Despite the revenue beat, the company faced a 19.4% revenue drop year-over-year and a significant decline in active coaches (from 19,500 to 10,200), partly attributed to competition from GLP-1 medications.
- While the coach base shrank, average revenue per active earning coach rose 54.1% to $7,064, and coach productivity increased 8%, partially offsetting the overall decline.
Medifast (NYSE: MED) reported a third-quarter 2026 loss of $0.19 per share, narrower than the estimated loss of $0.35 per share. Revenue was $72.00 million, above the $71.30 million estimate. Medifast sells weight-loss products through independent coaches. Its traditional weight-loss market also faces growing competition from GLP-1 medications.
Revenue fell 19.4% from a year earlier but remained within the company’s guidance range, as highlighted by MarketBeat. The number of active earning coaches dropped to about 10,200 from 19,500. Medifast says the rapid adoption of GLP-1 medications partly contributed to the decline and expects coach numbers to keep falling through year-end.
The smaller coach base generated more revenue per coach. Average revenue per active earning coach rose 54.1% to $7,064, while coach productivity increased an estimated 8% from the previous quarter. These gains helped support revenue, though they did not offset the year-over-year drop in the number of coaches.
The reported $0.19-per-share loss differs from the $1.57-per-diluted-share loss in Medifast’s financial results, as highlighted by Business Wire. The company reported a $17.50 million net loss and a $2.10 million non-GAAP adjusted net loss. Non-GAAP figures exclude certain costs, so they can show a different picture from standard accounting results.
